Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Capital Leases (2020 - 2025)

Rocket Pharmaceuticals' Capital Leases history spans 6 years, with the latest figure at $19.4 million for Q1 2025.

  • For Q1 2025, Capital Leases changed N/A year-over-year to $19.4 million; the TTM value through Mar 2025 reached $19.4 million, changed N/A, while the annual FY2024 figure was $19.4 million, 0.16% changed from the prior year.
  • Capital Leases for Q1 2025 was $19.4 million at Rocket Pharmaceuticals, roughly flat from $19.4 million in the prior quarter.
  • Across five years, Capital Leases topped out at $19.4 million in Q4 2024 and bottomed at $19.0 million in Q1 2021.
  • The 5-year median for Capital Leases is $19.3 million (2022), against an average of $19.3 million.
  • The largest annual shift saw Capital Leases rose 0.93% in 2021 before it rose 0.16% in 2024.
  • A 5-year view of Capital Leases shows it stood at $19.1 million in 2021, then rose by 0.65% to $19.3 million in 2022, then grew by 0.44% to $19.4 million in 2023, then increased by 0.16% to $19.4 million in 2024, then dropped by 0.01% to $19.4 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Capital Leases are $19.4 million (Q1 2025), $19.4 million (Q4 2024), and $19.4 million (Q3 2024).